| Follow-up period | 12 months prior to study entry | ||
---|---|---|---|---|
Measure* | Median | IQR | Median | IQR |
Duration of follow-up (years) | 5.29 | 2.62–8.58 | - | - |
Cumulative duration of GC use (years) | 0.80 | 0.15–2.56 | 0.23 | 0.05–0.67 |
Proportion of follow-up time on GCs (%) | 26.3 | 3.8–70.0 | 22.7 | 5.4–67.2 |
Average dose** (mg) | 7.5 | 5–15.3 | 10 | 5–20 |
Lowest dose** (mg) | 5 | 2.5–7.5 | 5 | 3–15 |
Highest dose** (mg) | 15 | 7.5–30 | 15 | 6–30 |